|
|
||||||||
1Department of Chemistry, Xavier University, 2Tulane University School of Medicine, Tulane/Veterans Affairs Environmental Astrobiology Center, and 3New Orleans Veterans Affairs Medical Center, New Orleans, Louisiana
Submitted 8 October 2003 ; accepted in final form 23 July 2004
Cubilin and megalin are giant glycoprotein receptors abundant on the luminal surface of proximal tubular cells of the kidney. We showed previously that light chains are a ligand for cubilin. As cubilin and megalin share a number of common ligands, we further investigated the ligand specificity of these receptors. Three lines of evidence suggest that light chains can also bind megalin: 1) anti-megalin antiserum largely displaces brush-border light chain binding and megalin-expressing BN-16 cell uptake more than anti-cubilin antiserum, 2) direct binding studies on isolated proteins using surface plasmon resonance techniques confirm that megalin binds light chains, and 3) light chains compete with known megalin ligands for brush-border membrane binding and BN-16 cell uptake. The megalin-light chain interaction is divalent ion dependent and similar for both
- and
-light chains. A fit of the data on light chain binding to megalin over a concentration range 0.0782.5 mg/ml leads to an estimated dissociation constant of 6 x 105 M, corresponding approximately to one light chain-binding site per megalin and in the same range for dissociation constants for cubilin binding. These data suggest that light chains bind the tandem megalin-cubilin complex. Megalin is the major mediator of light chain entry into megalin-expressing membrane such as the apical surface of proximal tubular epithelial cells.
cubilin; cancer; flow cytometry
This article has been cited by other articles:
![]() |
C. A. Hutchison, S. Harding, P. Hewins, G. P. Mead, J. Townsend, A. R. Bradwell, and P. Cockwell Quantitative Assessment of Serum and Urinary Polyclonal Free Light Chains in Patients with Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1684 - 1690. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Li, S. Balamuthusamy, E. E. Simon, and V. Batuman Silencing megalin and cubilin genes inhibits myeloma light chain endocytosis and ameliorates toxicity in human renal proximal tubule epithelial cells Am J Physiol Renal Physiol, July 1, 2008; 295(1): F82 - F90. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Li, K. S. Hering-Smith, E. E. Simon, and V. Batuman Myeloma light chains induce epithelial-mesenchymal transition in human renal proximal tubule epithelial cells Nephrol. Dial. Transplant., March 1, 2008; 23(3): 860 - 870. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-X. Wang and P. W. Sanders Immunoglobulin Light Chains Generate Hydrogen Peroxide J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1239 - 1245. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Sirac, F. Bridoux, C. Carrion, O. Devuyst, B. Fernandez, J.-M. Goujon, C. E. Hamel, J.-C. Aldigier, G. Touchard, and M. Cogne Role of the monoclonal {kappa} chain V domain and reversibility of renal damage in a transgenic model of acquired Fanconi syndrome Blood, July 15, 2006; 108(2): 536 - 543. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Gonzalez-Villalobos, R. B. Klassen, P. L. Allen, K. Johanson, C. B. Baker, H. Kobori, L. G. Navar, and T. G. Hammond Megalin binds and internalizes angiotensin-(1-7) Am J Physiol Renal Physiol, May 1, 2006; 290(5): F1270 - F1275. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Arimura, M. Li, V. Batuman, W.F. Clark, A.K. Stewart, G.A. Rock, M. Sternbach, D.M. Sutton, B.J. Barrett, A.P. Heidenheim, et al. Cast Nephropathy in Myeloma--Does PACAP38, a New Member of the Vasoactive Intestinal Peptide Family, Open a Therapeutic Window?: Potential Protective Action of Pituitary Adenylate Cyclase-Activiating Polypeptide (PACAP38) on In Vitro and In Vivo Models of Myeloma Kidney Injury. Blood 107: 661-668, 2006 J. Am. Soc. Nephrol., April 1, 2006; 17(4): 911 - 919. [Full Text] [PDF] |
||||
![]() |
A. Arimura, M. Li, and V. Batuman Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury Blood, January 15, 2006; 107(2): 661 - 668. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |